vs
Beam Therapeutics Inc.（BEAM）与MP Materials Corp.（MP）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是MP Materials Corp.的1.3倍（$114.1M vs $90.6M），Beam Therapeutics Inc.净利率更高（214.1% vs -8.8%，领先222.9%），Beam Therapeutics Inc.同比增速更快（279.5% vs 49.1%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
MP Materials Corp.是总部位于美国的稀土材料生产商，拥有并运营加利福尼亚州芒廷帕斯矿，这是西半球唯一在产的稀土开采及加工设施，所产核心材料可广泛应用于电动汽车、风力发电机、国防工业等多个关键领域。
BEAM vs MP — 直观对比
营收规模更大
BEAM
是对方的1.3倍
$90.6M
营收增速更快
BEAM
高出230.4%
49.1%
净利率更高
BEAM
高出222.9%
-8.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $90.6M |
| 净利润 | $244.3M | $-8.0M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | — |
| 净利率 | 214.1% | -8.8% |
| 营收同比 | 279.5% | 49.1% |
| 净利润同比 | 370.4% | 64.8% |
| 每股收益（稀释后） | $2.53 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMMP
| Q1 26 | — | $90.6M | ||
| Q4 25 | $114.1M | $52.7M | ||
| Q3 25 | — | $53.6M | ||
| Q2 25 | — | $57.4M | ||
| Q1 25 | — | $60.8M | ||
| Q4 24 | — | $61.0M | ||
| Q3 24 | — | $62.9M | ||
| Q2 24 | — | $31.3M |
净利润BEAMMP
| Q1 26 | — | $-8.0M | ||
| Q4 25 | $244.3M | $9.4M | ||
| Q3 25 | — | $-41.8M | ||
| Q2 25 | — | $-30.9M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | — | $-25.5M | ||
| Q2 24 | — | $-34.1M |
营业利润率BEAMMP
| Q1 26 | — | — | ||
| Q4 25 | -15.3% | -7.0% | ||
| Q3 25 | — | -125.2% | ||
| Q2 25 | — | -76.5% | ||
| Q1 25 | — | -57.2% | ||
| Q4 24 | — | -72.1% | ||
| Q3 24 | — | -62.8% | ||
| Q2 24 | — | -171.1% |
净利率BEAMMP
| Q1 26 | — | -8.8% | ||
| Q4 25 | 214.1% | 17.9% | ||
| Q3 25 | — | -78.0% | ||
| Q2 25 | — | -53.8% | ||
| Q1 25 | — | -37.2% | ||
| Q4 24 | — | -36.6% | ||
| Q3 24 | — | -40.5% | ||
| Q2 24 | — | -108.9% |
每股收益（稀释后）BEAMMP
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $2.53 | $0.07 | ||
| Q3 25 | — | $-0.24 | ||
| Q2 25 | — | $-0.19 | ||
| Q1 25 | — | $-0.14 | ||
| Q4 24 | — | $-0.12 | ||
| Q3 24 | — | $-0.16 | ||
| Q2 24 | — | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $1.7B |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $1.2B | $2.0B |
| 总资产 | $1.5B | $3.8B |
| 负债/权益比越低杠杆越低 | — | 0.51× |
8季度趋势，按日历期对齐
现金及短期投资BEAMMP
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $261.5M | ||
| Q1 25 | — | $198.3M | ||
| Q4 24 | — | $282.4M | ||
| Q3 24 | — | $284.4M | ||
| Q2 24 | — | $295.6M |
总债务BEAMMP
| Q1 26 | — | $1.0B | ||
| Q4 25 | — | $998.7M | ||
| Q3 25 | — | $997.3M | ||
| Q2 25 | — | $910.8M | ||
| Q1 25 | — | $909.8M | ||
| Q4 24 | — | $908.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BEAMMP
| Q1 26 | — | $2.0B | ||
| Q4 25 | $1.2B | $2.0B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B |
总资产BEAMMP
| Q1 26 | — | $3.8B | ||
| Q4 25 | $1.5B | $3.9B | ||
| Q3 25 | — | $3.8B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.4B |
负债/权益比BEAMMP
| Q1 26 | — | 0.51× | ||
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.88× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $-1.9M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMMP
| Q1 26 | — | $-1.9M | ||
| Q4 25 | $-83.3M | $-46.9M | ||
| Q3 25 | — | $-42.0M | ||
| Q2 25 | — | $-3.7M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | — | $-6.8M | ||
| Q2 24 | — | $30.8M |
自由现金流BEAMMP
| Q1 26 | — | — | ||
| Q4 25 | $-87.0M | $-109.3M | ||
| Q3 25 | — | $-92.5M | ||
| Q2 25 | — | $-32.7M | ||
| Q1 25 | — | $-93.7M | ||
| Q4 24 | — | $-11.2M | ||
| Q3 24 | — | $-53.3M | ||
| Q2 24 | — | $-15.6M |
自由现金流率BEAMMP
| Q1 26 | — | — | ||
| Q4 25 | -76.3% | -207.4% | ||
| Q3 25 | — | -172.8% | ||
| Q2 25 | — | -56.9% | ||
| Q1 25 | — | -154.0% | ||
| Q4 24 | — | -18.3% | ||
| Q3 24 | — | -84.7% | ||
| Q2 24 | — | -50.1% |
资本支出强度BEAMMP
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 118.5% | ||
| Q3 25 | — | 94.3% | ||
| Q2 25 | — | 50.5% | ||
| Q1 25 | — | 50.1% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 73.8% | ||
| Q2 24 | — | 148.7% |
现金转化率BEAMMP
| Q1 26 | — | — | ||
| Q4 25 | -0.34× | -4.97× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
MP
| Materials Segment | $72.2M | 80% |
| Magnetics Segment | $21.1M | 23% |
